| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received February 21, 2006
Accepted on June 29, 2006
CLINICAL SCIENCE: Cell Biology |
1,
,
,
,
yna Nowak
,
,
Departments of *Internal Medicine,
Physiology, and
Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Little Rock, Arkansas; and
Mouse Cancer Genetics Program, National Cancer Institute, Frederick, Maryland
1 To whom correspondence should be addressed. E-mail: PricePeterM{at}uams.edu.
| Abstract |
|---|
Cisplatin is one of the most effective chemotherapeutics, but its usefulness is limited by its toxicity to normal tissues, including cells of the kidney proximal tubule. The purpose of these studies was to determine the mechanism of cisplatin cytotoxicity. It was shown in vivo that cisplatin administration induces upregulation of the gene for the p21 cyclin-dependent kinase (cdk) inhibitor in kidney cells. This protein is a positive effector on the fate of cisplatin-exposed renal tubule cells in vivo and in vitro; adenoviral transduction of p21 completely protected proximal tubule cells from cisplatin toxicity. Herein is reported that cdk2 inhibitory drugs protect kidney cells in vivo and in vitro, that transduction of kidney cells in vitro with dominant-negative cdk2 also protected, and that cdk2 knockout cells were resistant to cisplatin. The cdk2 knockout cells regained cisplatin sensitivity after transduction with wild-type cdk2. It is concluded that cisplatin cytotoxicity depends on cdk2 activation and that the mechanism of p21 protection is by direct inhibition of cdk2. This demonstrated the involvement of a protein that previously was associated with cell-cycle progression with pathways of apoptosis. It also was demonstrated that this pathway of cisplatin-induced cell death can be interceded in vivo to prevent nephrotoxicity.
This article has been cited by other articles:
![]() |
M. Jiang and Z. Dong Regulation and Pathological Role of p53 in Cisplatin Nephrotoxicity J. Pharmacol. Exp. Ther., November 1, 2008; 327(2): 300 - 307. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. B. Sanz, B. Santamaria, M. Ruiz-Ortega, J. Egido, and A. Ortiz Mechanisms of Renal Apoptosis in Health and Disease J. Am. Soc. Nephrol., September 1, 2008; 19(9): 1634 - 1642. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Yu, J. Megyesi, and P. M. Price Cytoplasmic initiation of cisplatin cytotoxicity Am J Physiol Renal Physiol, July 1, 2008; 295(1): F44 - F52. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Sheikh-Hamad Cisplatin-induced cytoxicity: is the nucleus relevant? Am J Physiol Renal Physiol, July 1, 2008; 295(1): F42 - F43. [Full Text] [PDF] |
||||
![]() |
A. Weidemann, W. M. Bernhardt, B. Klanke, C. Daniel, B. Buchholz, V. Campean, K. Amann, C. Warnecke, M. S. Wiesener, K.-U. Eckardt, et al. HIF Activation Protects From Acute Kidney Injury J. Am. Soc. Nephrol., March 1, 2008; 19(3): 486 - 494. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Lechner, N. A. Malloth, P. Jennings, D. Heckl, W. Pfaller, and T. Seppi Opposing roles of EGF in IFN-{alpha}-induced epithelial barrier destabilization and tissue repair Am J Physiol Cell Physiol, December 1, 2007; 293(6): C1843 - C1850. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Yu, J. Megyesi, R. L. Safirstein, and P. M. Price Involvement of the CDK2-E2F1 pathway in cisplatin cytotoxicity in vitro and in vivo Am J Physiol Renal Physiol, July 1, 2007; 293(1): F52 - F59. [Abstract] [Full Text] [PDF] |
||||
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673